Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Naheema S. Gordon"'
Autor:
Naheema S. Gordon, Elspeth K. McGuigan, Michaela Ondasova, Jennifer Knight, Laura A. Baxter, Sascha Ott, Robert K. Hastings, Maurice P. Zeegers, Nicholas D. James, K. K. Cheng, Anshita Goel, Minghao Yu, Roland Arnold, Richard T. Bryan, Douglas G. Ward
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-4 (2024)
Abstract Background and aims Several non-invasive tests for detecting bladder cancer (BC) are commercially available and are based on detecting small panels of BC-associated mutations and/or methylation changes in urine DNA. However, it is not clear
Externí odkaz:
https://doaj.org/article/948476a9f2e2449e9f9c0f8d0705374d
Autor:
Anshita Goel, Douglas G. Ward, Boris Noyvert, Minghao Yu, Naheema S. Gordon, Ben Abbotts, John K. Colbourne, Stephen Kissane, Nicholas D. James, Maurice P. Zeegers, Kar Keung Cheng, Jean-Baptiste Cazier, Celina M. Whalley, Andrew D. Beggs, Claire Palles, Roland Arnold, Richard T. Bryan
Publikováno v:
Genome Medicine, Vol 14, Iss 1, Pp 1-16 (2022)
Abstract Background Three-quarters of bladder cancer patients present with early-stage disease (non-muscle-invasive bladder cancer, NMIBC, UICC TNM stages Ta, T1 and Tis); however, most next-generation sequencing studies to date have concentrated on
Externí odkaz:
https://doaj.org/article/d1aa928db1214c45b71b986bd13f2d0c
Autor:
Naheema S. Gordon, Nada Humayun-Zakaria, Anshita Goel, Ben Abbotts, Maurice P. Zeegers, K.K. Cheng, Nicholas D. James, Roland Arnold, Richard T. Bryan, Douglas G. Ward
Publikováno v:
European Urology Open Science, Vol 38, Iss , Pp 88-95 (2022)
Background: Mutations in STAG2 cause complete loss of STAG2 protein in approximately one-third of non–muscle-invasive bladder cancers (NMIBCs). STAG2 protein expression is easily determined via immunohistochemistry (IHC) and published data suggest
Externí odkaz:
https://doaj.org/article/cd7f6e392dac489ca6158fd808a151a1
Autor:
Alexander C. Dowell, Haydn Munford, Anshita Goel, Naheema S. Gordon, Nicholas D. James, K. K. Cheng, Maurice P. Zeegers, Douglas G. Ward, Richard T. Bryan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The use of immune checkpoint blockade, in particular PD-1 and PD-L1 inhibitors, is now commonplace in many clinical settings including the treatment of muscle-invasive bladder cancer (MIBC). Notwithstanding, little information exists regarding the ex
Externí odkaz:
https://doaj.org/article/a6407fd65c5047b08c56e5b712248dad
Autor:
Anshita Goel, Douglas G. Ward, Naheema S. Gordon, Ben Abbotts, Maurice P. Zeegers, K. K. Cheng, Nicholas D. James, Richard T. Bryan, Roland Arnold
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Circularized transcript isoforms due to back-splicing are increasingly being reported in different tissues types and pathological states including cancer. Since these circular RNAs (circRNAs) are more stable than linear messenger RNA their identifica
Externí odkaz:
https://doaj.org/article/9ffbcd7e5e2d402b91b0bbbbb95337a5
Autor:
Sarah R. Ambrose, Naheema S. Gordon, James C. Goldsmith, Wenbin Wei, Maurice P. Zeegers, Nicholas D. James, Margaret A. Knowles, Richard T. Bryan, Douglas G. Ward
Publikováno v:
Proteomes, Vol 3, Iss 3, Pp 266-282 (2015)
Developing a urine test to detect bladder tumours with high sensitivity and specificity is a key goal in bladder cancer research. We hypothesised that bladder cancer-specific glycoproteins might fulfill this role. Lectin-ELISAs were used to study the
Externí odkaz:
https://doaj.org/article/28fec3d36dba49109507bb6b2f355358
Autor:
Douglas G. Ward, Laura Baxter, Sascha Ott, Naheema S. Gordon, Junhui Wang, Prashant Patel, Kim Piechocki, Lee Silcock, Chris Sale, Maurice P. Zeegers, K.K. Cheng, Nicholas D. James, Richard T. Bryan
Publikováno v:
European Urology Oncology. Elsevier
BACKGROUND: There is an unmet need for an accurate, validated, noninvasive test for diagnosing and monitoring bladder cancer (BC). Detection of BC-associated mutations in urinary DNA via targeted deep sequencing could meet this need.OBJECTIVE: To tes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66a84fdec20596e02a7fd6b05cfc132d
https://doi.org/10.1016/j.euo.2022.03.005
https://doi.org/10.1016/j.euo.2022.03.005
Urine DNA for monitoring chemoradiotherapy response in muscle-invasive bladder cancer: a pilot study
Autor:
Roland Arnold, Syed A. Hussain, Richard T. Bryan, Wenyu Liu, Richard Viney, Douglas G. Ward, Naheema S. Gordon, Nicholas D. James, Timur Mitin, Sarah Pirrie, Baljit Kaur, Daniel Ford, Anshita Goel, Laura Baxter, Mary A. Wood, Anjali Zarkar, Reid F. Thompson
Publikováno v:
BJU internationalReferences. 129(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd61a989f847a15931b0305208e09d5d
https://pubmed.ncbi.nlm.nih.gov/34491610
https://pubmed.ncbi.nlm.nih.gov/34491610
Autor:
Maurice P. Zeegers, Yongwon Ju, Naheema S. Gordon, Richard T. Bryan, Douglas G. Ward, Nicholas D. James, Ilaria J. Russo, K.K. Cheng
Publikováno v:
Bladder Cancer, 4(1), 41-48. IOS Press
Background: TERT promotor mutations are present in >75% of bladder tumours; these mutations are also detectable in urine. Previous studies have used urinary pellet DNA, and semi-quantitative methods unsuitable for detecting very low mutant allele fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32191c28e8a03552dbd9823c95ff7ee5
https://content.iospress.com:443/download/bladder-cancer/blc170152?id=bladder-cancer/blc170152
https://content.iospress.com:443/download/bladder-cancer/blc170152?id=bladder-cancer/blc170152
Autor:
Sarah Leonard, Jennifer Anderton, Yuk Ting Ma, Ciaran B J Woodman, David Huen, Claire D. James, Daniel H. Palmer, Naheema S. Gordon
Publikováno v:
Oncotarget
The ability to develop a comprehensive panel of treatment predicting factors would significantly improve our ability to stratify patients for cytotoxic or targeted therapies, and prevent patients receiving ineffective treatments. We have investigated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e215c2ba741c1f07f611594e7a4d9cb
https://doi.org/10.18632/oncotarget.18879
https://doi.org/10.18632/oncotarget.18879